Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination.

"Tamás Molnár has received speaker’s honoraria from MSD, AbbVie, Egis, Goodwill Pharma, Takeda, Pfizer, Janssen, Sandoz, MundiPharma, Phytotec, Roche, Fresenius, and Teva. Klaudia Farkas has received speaker’s honoraria from AbbVie, Janssen, Ferring, Takeda, and Goodwill Pharma. PB, MH, KSZ, MR, AB, AF, RB, ZSZ, JF, and PM have no conflict of interest to disclose."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by research grants from the National Research, Development and Innovation Office (Grant ID: 143549, 125377, 129266, 139269 and 134863) and the New National Excellence Programme of the Ministry of Human Capacities (UNKP-22-3-SZTE-233 to BP, UNKP-22-4 -SZTE-293 to BR, UNKP-22-3-SZTE-278 to RT, UNKP-22-4-SZTE-296 to FA) and by a J János Bolyai Research Grant nos Bolyai Research Grant (BO/00723/22) and a Géza Hetényi Research Grant (to FK, RM and BA) from the Faculty of Medicine, University of Szeged."

"Ethics approval and consent to participate: The study was approved by the National Institute of Pharmacy and Nutrition according to the Scientific Research Ethics Committee of the Hungarian Medical Research Council’s proposal (Registration No. ETT TUKEB IV/861-1/2021/EKU) and by the Regional and Institutional Human Medical Biological Research Ethics Committee, University of Szeged (approval No.: RKEB 4937). All subjects provided written informed consent prior to study participation. The study was conducted according to the principles of the Declaration of Helsinki."